reason report
investor dinner highlight top-lin growth potenti driven
global healthcar confer host investor dinner
cfo jay saccaro vice-president ir clare trachtman
share perform well last month
meet strengthen convict estim
upsid stori top bottom line thu increment
share upsid takeaway dinner includ
innov becom much meaning piec stori
via intern acquisit geograph expans given
good portion innov involv launch exist product
new geographi innov cycl essenti de-risk
long-term increment margin expans close tie longer-
term cost effici product innov overal came away
even bullish bax top bottom-lin growth opportun
us runway growth acceler increment margin
expans long believ continu deliv top-tier ep
growth profil forese futur upsid sale
free cash flow give manag even flexibl reinvest
busi optimize/enh portfolio
medic suppli devic
pt deriv rang
dcf valuat deriv
base case upsid scenario
supplement ev/fcf ev/
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu mm ep includ stock compens expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share outperform price target nine consecut
beat rais ep quarter sinc spin oper margin alreadi track ahead
manag current long-rang plan increasingli strong free cash flow gener
believ post-spin new turnaround stori still room signific upsid
believ increment margin upsid potenti alreadi price believ magnitud
sale growth reacceler potenti free cash flow gener still underappreci
level increasingli becom strong free cash flow gener stori free cash
flow target vs expect
last may analyst day potenti upsid free cash flow
view increas financi flexibl invest busi drive even
faster sale growth acceler invest inorgan outsid opportun
supplement top- bottom-lin growth
given compani solid execut to-dat steadi stream upcom new product launch
addit clari fill gener inject busi increasingli confid
continu drive upsid recent updat long-term growth margin target
believ margin expans stori alreadi least partli price stock
manag current guid oper margin
deliv oper margin margin improv clearli
track ahead schedul believ ultim potenti oper margin like well
line compar large-cap med-tech compani see room upsid
margin ramp believ major upsid alreadi price share level
sale perspect also see potenti upsid current top-lin growth target
compound-annual-growth-rate time-frame driven new product launch geograph
expans someth feel underappreci street pipelin biggest
driver sale growth acceler next five year expect launch
new product new product expect make total sale
ramp expect signific growth pd periton dialysi gener inject
biosurgeri core growth contributor drive top line grow solid mid-
singl digit higher
overal find bax margin expans stori compel believ investor
underappreci bax sale growth reacceler stori also compani cash-
gener capabl believ ebitda repres relev
measur valu compani vs price earn combin
discount cash flow analysi ev/ebitda ev/fcf arriv month price
takeaway investor dinner rais stori intact
global healthcar confer host investor dinner cfo jay
saccaro vice-president ir clare trachtman share perform well last
month meet strengthen convict estim upsid
stori top bottom line thu increment share upsid
takeaway dinner includ innov becom much meaning piec
stori via intern acquisit geograph expans given good
portion innov involv launch exist product new geographi innov
cycl essenti de-risk long-term increment margin expans close
tie long-term cost effici product innov overal came away even
bullish bax top bottom-lin growth opportun us runway growth
acceler increment margin expans long believ continu deliv
top-tier ep growth profil forese futur upsid sale free cash flow
give manag even flexibl reinvest busi optimize/enh
sustain long-term growth driven product innov
manag expect new product defin launch geograph
entranc within year contribut top-lin growth drive even
meaning growth next year corpor level saccaro note
abl grow solid execut in-lin overal end user market
growth beyond note abl achiev least growth help
new product launch geograph expans top-lin growth possibl
increment contribut innov segment level highlight import
product launch could drive sale upsid beyond hdx expand
hemodialysi therapi theranova point-of-car pd periton dialysi addit
clari portfolio fulli address fast-grow gener
inject market growth rate sever product launch biosurgeri
least bring busi back market growth sever year under-perform
histori pre-spin cfo saccaro vp-ir trachtman note
disconnect commerci side busi ceo almeida took
helm scientist would work project without customer-fac experi
without real account organ structur chang drive
product scientist report busi head vs chief medic offic previous
visit custom regular basi gather feedback obvious account within
organ chang dramat idea transform customer-pref
product rather pure concept lastli pre-spin larg dedic
bioscienc busi low level devic busi post-spin
dedic meaning amount dollar rebuild/reinvigor pipelin
blockbust product dictat stori essenti stapl product drive
sustain long-term growth saccaro trachtman note product portfolio
pipelin greatli diversifi blockbust product contribut disproportion
major bax product essenti life-sav product launch gener sustain
growth mani year evidenc durabl growth iv therapi busi last
monet innov geograph expans manag view obtain licens
alreadi launch product uncov region effici low-risk way deliv
innov top-lin growth becom increasingli import compon stori
geograph expans effect de-risk execut risk
near-term margin expans driven continu control innov drive
compani alreadi track ahead oper margin guidanc
saccaro see improv beyond target cite bcr exampl similar
margin expans profil saccaro also note last year equal
focus cost reduct innov take longer innov initi bear
fruit low-hang fruit seemingli pick expect margin improv
portfolio transform innov vs cost reduct manag expect major
new product launch margin accret given innov new product gener
higher gross margin steadi stream higher-margin dispos revenu cost
reduct side saccaro still see room improv complic initi
move busi activ high-cost locat low-cost locat gener
take time show number
deploy focus reinvest small-scal much like larg
bax capit deploy strategi remain unchang strong gener
zero net debt posit saccaro note net debt ebitda would
appropri leverag ratio compani approach time cash
deploy reinvest intern capital-expenditure drive organ growth dividend
compani target pay-out ratio long term share buyback
stock trade discount manag estim intrins valu opportun
creat sharehold valu notabl manag commentari suggest larg deal
unlik given alreadi stretch valuat market today saccaro note major
acquisit target bring less thu reason target
ask criteria make acquisit saccarro mention asset fit
portfolio compet advantag logic buyer
deal size limit larg deal unlik environ
next month believ share trade rang
dcf valuat deriv base case upsid scenario supplement
ev/fcf ev/ebitda analys ev/ebitda perspect valuat right line
group includ bcr ew
estim
failur execut margin expans initi new product launch delay possibl
acquisit either dilut perceiv further baxter growth goal could
pressur stock
dollar million except asp
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report leerink partner estim
